Carsgen Therapeutics Holding Stock price
Compare with Peer Group
Is Carsgen Therapeutics Holding a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.
Key metrics
Carsgen Therapeutics Holding Stock Analysis
Analyst Opinions
9 Analysts have issued a Carsgen Therapeutics Holding forecast:
Analyst Opinions
9 Analysts have issued a Carsgen Therapeutics Holding forecast:
Don't miss a Thing! We will send you all news about Carsgen Therapeutics Holding directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 468 full-time employees. The company went IPO on 2021-06-18. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The firm conducts its business in the domestic and overseas markets.
| Head office | Cayman Islands |
| CEO | Mr. Li |
| Employees | 362 |
| Website | www.carsgen.com |


